医保基金监管已覆盖"参保人—医疗机构—医药代表—药贩子—药店"完整非法利益链条。 从江西医药代表中药配方颗粒行贿案，上海医疗耗材商行贿案、医药代表篡改检测报告骗保案曝光，到 鞍山某医院药剂科主任受贿落马，再到上海退休人员王某涉及的药品倒卖"黑色产业链"被斩断，10余天 内国家医保局连续公布了5起涉及医保基金的典型案件。 这些案件清晰地表明，医保基金监管已经覆盖到了"参保人—医疗机构—医药代表—药贩子—药店"完整 非法利益链条。 北京中医药大学卫生健康法治研究与创新转化中心主任邓勇对第一财经表示，国家医保局密集公布这些 司法案例，释放出了对医疗腐败零容忍且严惩不贷、聚焦医保基金全链条守护、固化常态化监管机制这 三大核心信号。 医保局曝光医药购销贿赂案例 11月20日，25日，28日，国家医保局以"根据法院刑事判决书摘录"的形式连续公布了"黄某云涉中药配 方颗粒行贿案""上海某科贸商行涉支架球囊行贿案""鞍山市双山医院药剂科主任刘某红受贿案"的违法 犯罪细节。 邓勇表示，这些案例表明对医疗腐败零容忍且严惩不贷。不管是医药代表骗保及医疗耗材代理商行贿被 判刑，都体现司法层面从重处罚的态度，即便有自首、退赃等情节，也 ...

Group 1 - The National Healthcare Security Administration of China disclosed a case of fraud involving a pharmaceutical representative who altered genetic testing reports to meet personal sales targets, leading to the use of targeted cancer drugs in patients who did not meet the necessary criteria, resulting in losses to the medical insurance fund [1] - The case serves as a warning about the importance of adhering to drug indications and genetic mutation conditions to ensure effective targeted therapy, emphasizing that legal consequences are in place for violations [1] Group 2 - Hainan Haiyao announced that its stock experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% over two consecutive trading days [2] - The company confirmed that there were no violations of information disclosure regulations, suggesting that investors should monitor official information disclosure channels for rational investment decisions [2] Group 3 - Eli Lilly became the first pharmaceutical company to surpass a market capitalization of $1 trillion, achieving this milestone on November 21 [3] - The company's weight loss drug, Zepbound, which is set to launch at the end of 2023, has already captured a significant share of new obesity drug prescriptions, surpassing Novo Nordisk's Wegovy [3] - This achievement marks a shift in the "trillion-dollar club," traditionally dominated by tech giants, highlighting Eli Lilly's emergence as a leader in the metabolic health sector [3]